Atlanta Regional Community Clinical Oncology Program offers the National Cancer Institute excellent resources. Since ARCCOP received funding in 1983, many of the CCOP's initial aims have been achieved, specifically: the development of standards for investigator participation; establishment of procedures for investigational drug management; development and implementation of protocol selection procedures; formalization and expansion of cancer control activities; and development and refinement of the data management system. While CCOP will continue to meet these goals, ARCCOP will also progress and expand through the achievement of several new objectives: to coordinate and expand existing regional hospital resources to support the development of ARCCOP; to meet and surpass NCI requirements for clinical and cancer control protocol accrual; to collaborate with SWOG, RTOG and M.D. Anderson to offer regional cancer patients and physician participants access to current research trials; refine and expand our data management system to assure the accurate collection, quality control and timely transmission of data to research bases; to maintain high standard of participation for CCOP investigators while expanding the number of highly qualified participants; to increase the involvement of primary care physicians in the cancer program and make them aware of the availability of existing protocols; to involve other regional institutions in formal clinical trials, gradually expanding the availability of NCI protocols to other regional physicians. The Atlanta Regional Community Clinical Oncology Program possesses several unique, distinguishing attributes. The ARCCOP has unique resources in GYN oncology, due to the expertise of our nationally known Principal Investigator, Dr. Ernest Franklin. Significant local contributions, which supplement funds from NCI, secure our CCOP's financial foundation. Strong, high quality data management is yet another attribute of our CCOP. In addition, the ARCCOP has a track record of high levels of ongoing accruals, 84 therapeutic and 58 cancer control credits this year alone. Given the short period of time that ARCCOP has been operating, it is important to note that these accrual figures place our CCOP among those that are the oldest and best performing. The Atlanta Regional Community Clinical Oncology Program has made, and will continue to make, a significant contribution to the National Cancer Institute's Community Clinical Oncology Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA045450-04
Application #
3558625
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1987-08-01
Project End
1994-05-31
Budget Start
1990-06-01
Budget End
1991-05-31
Support Year
4
Fiscal Year
1990
Total Cost
Indirect Cost
Name
St. Joseph's Hospital (Atlanta)
Department
Type
DUNS #
City
Atlanta
State
GA
Country
United States
Zip Code
30342
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Friedberg, Jonathan W; Unger, Joseph M; Burack, W Richard et al. (2014) R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Haematol 166:382-9
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33

Showing the most recent 10 out of 52 publications